OnCo
technologiesTechnologyPhase 3

Systematic drug repurposing

Testing cheap old drugs, aspirin, metformin, statins, beta-blockers, as cancer treatments, because they are safe, available and sometimes work.

Large randomised trials of repurposed agents have given sobering results: metformin did not improve invasive disease-free survival in the adjuvant breast cancer trial MA.32 (NCT01101438), while aspirin continues to be tested for adjuvant benefit (Add-Aspirin, NCT02804815) and is established in Lynch syndrome prevention. AI screening of prescription and expression databases now proposes candidates faster than trials can test them, and funding for non-proprietary agents is the real bottleneck.

Generic schematic · not to scale · placeholder for the drug discovery front
Guide RNA library · Knockout → dependency

How it works

Approved drugs with known safety are tested against cancer endpoints, either on mechanistic grounds or on signals mined from real-world prescription data.

Strengths
  • Known safety and cost, so adoption is immediate if positive
  • Attractive for prevention and low-resource settings
  • AI can prioritise candidates from existing data
Limitations
  • No commercial sponsor, so trials are slow and underfunded
  • Observational signals are heavily confounded
  • Major trials have been negative

Latest papers

top
Latest papers · live from Europe PMC
Open in Europe PMC

Query for this technology: (TITLE:"Systematic drug repurposing" OR ABSTRACT:"Systematic drug repurposing") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Systematic drug repurposing, not a curated reading list.

Connected

15top

Pages like this

not linked directly; found by shared links